

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™

RRID:AB_2726170

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-563, RRID:AB_2726170

Antibody Information

URL: http://antibodyregistry.org/AB_2726170

Proper Citation: Miltenyi Biotec Cat# 130-113-563, RRID:AB_2726170

Target Antigen: CD159a (NKG2A)

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-098-812. (RRID:AB_2655386).

Antibody Name: CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™

Description: This monoclonal targets CD159a (NKG2A)

Target Organism: human

Clone ID: clone REA110

Antibody ID: AB_2726170

Vendor: Miltenyi Biotec

Catalog Number: 130-113-563

Record Creation Time: 20250820T001519+0000

Record Last Update: 20250820T074716+0000

Ratings and Alerts

No rating or validation information has been found for CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™.

No alerts have been found for CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mensching L, et al. (2025) HIV-1 infection of macrophages differentially primes NK-cell cytotoxicity and proinflammatory cytokine production. *iScience*, 28(7), 112879.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Hofman T, et al. (2024) IFN γ mediates the resistance of tumor cells to distinct NK cell subsets. *Journal for immunotherapy of cancer*, 12(7).

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. *Cell stem cell*, 31(9), 1376.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.

Routhu NK, et al. (2021) A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. *Immunity*, 54(3), 542.